Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.  For further information please visit www.signumbiosciences.com.


'/>"/>
SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan 23, 2017 Research and Markets ... Analysis & Trends - Product - Forecast to 2025" report to ... Report Highlights: ... and future market trends to identify the investment opportunities ... Key market trends across the business segments, Regions and ...
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, Florida ... eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen ... der Verkauf ihrer bestehenden Produkte im Tausch gegen ... Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... , ... "ProRandom is a set of camera tools that allow video editors to integrate up ... X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video ... footage. ProRandom works by using a virtual camera to create the illusion of a ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals about ... been developed for use by nutrition educators and influencers within the public ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate ... For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery ... an additional $25 free. Or, spend $200 and get $50 free. , “A lot ...
(Date:1/22/2017)... Viejo, California (PRWEB) , ... January 22, 2017 , ... ... Photo Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin ... the Generators browser to place in the FCPX timeline. Presets include scenes ...
Breaking Medicine News(10 mins):